

Classification of atherothrombotic events in myocardial infarctions survivors with supervised machine learning using data from an electronic health record system

Holger Kunz^a, Laura Pasea^a, Spiros Denaxas^a

^a*Institute of Health Informatics, University College London, United Kingdom*

Abstract. The aim was to build a prediction model for subsequent atherothrombotic events for patients who survived a myocardial infarction. The dataset contained 7,582 patients from a national Electronic Health Record. The prediction is a binary outcome (event and no event) in a period of five years after a myocardial infarction. Different classifiers were tested and XGBoost achieved the best F1-score=0.76. Top features are: imd_score, age_at_entry, egfr_ckdepi_base, height, and SBP_base.

Keywords. classification, atherothrombosis, supervised machine learning, prognosis

1. Introduction

The aim is to use data from Electronic Health Records (EHR) to predict atherothrombotic events as a binary outcome (event and no event) in a period of five years after a myocardial infarction. Data from patients who were still alive one year after their last acute MI from the CALIBER programme [1] were used. CALIBER uses three national structured EHR sources: primary care health records (coded diagnoses, clinical measurements, and prescriptions) from the Clinical Practice Research Datalink (CPRD); coded hospital discharges (Hospital Episode Statistics, HES); and death registrations.

2. Methods

For the supervised classification a dataset of 7,582 patients was used. Follow-up started at year 1 after index acute MI, and patients were censored at the earliest data of the endpoints, death or 5 years of follow-up. The endpoint is defined as a binary outcome whether a patient has an atherothrombotic event in a period of five years. In total 62 clinical features were used. Classifiers such as SVM, XGBoost, Neural Network (MLP), and Naïve Bayes were applied. Five-fold cross-validation was used for hyperparameter tuning on 5307 instances. For the final evaluation 2275 instances were used. The optimization focused on the F1-score as the dataset was imbalanced. The implementation was done in Python.

Results

The best F1-score has XGBoost with $F1=0.76$ and $AUROC=0.83$. The best AUROC has the SVM with $AUROC=0.84$ and $F1=0.74$. MLP has an $AUROC=0.82$ and $F1=0.75$. Naïve Bayes has an $AUROC=0.79$ and $F1=0.69$. Testing the XGBoost-model with 2275 instances achieved a confusion matrix of 1244 (TN), 327 (FN), 534 (TP), and 170 (FP). The following top five features were derived with the information weight from XGBoost: 1 imd_score (0.089), 2 age_at_entry (0.0698), 3 egfr_ckdepi_base (0.0578), 4 height (0.0508), and 5 SBP_base (0.048). Figure 1 shows a comparison of different classifiers.




Figure 1: Comparison of classifiers

3. Discussion and Conclusion

The applied classifiers achieved a reasonable performance. XGBoost has the advantage to provide a feature ranking that can further inform clinicians. Similar discrete single time point models with a fixed time period have been used for the prognosis of cancer [2]. The dataset can also be used for time-to-event analysis [3]. A limitation of this study is the usage of a proportion of the data for testing purposes to achieve a robust and reliable estimate on unseen data. Finally, it may be concluded that the performance of the prediction algorithms and the derived feature ranking could be useful for a potential clinical decision support system (DSS). A further feasibility study could evaluate its usage in clinical practice.

References

1. Denaxas SC, George J, Herrett E, Shah AD, Kalra D, Hingorani AD, et al. Data resource profile: Cardiovascular disease research using linked bespoke studies and electronic health records (CALIBER). *Int J Epidemiol*. 2012;41(6):1625–38.
2. Delen D, Walker G, Kadam A. Predicting breast cancer survivability: A comparison of three data mining methods. *Artif Intell Med*. 2005;34(2):113–27.
3. Pasea L, Chung SC, Pujades-Rodriguez M, Moayyeri A, Denaxas S, Fox KAA, et al. Personalising the decision for prolonged dual antiplatelet therapy: Development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. *Eur Heart J*. 2017;38(14):1048–55.